Press Releases

Date Title
April 15, 2015
Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidate
Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study.  This study is
February 12, 2015
ONS-3010 (Humira®/adalimumab biosimilar) meets primary endpoints in first clinical study
Cranbury, NJ – February 12, 2015 — Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars,announced today that ONS-3010, its adalimumab (Humira®) biosimilar candidate met the primary endpoints in its first clinical study.
October 7, 2014
Oncobiologics Appoints Dr. Todd C. Brady to its Board of Directors
Cranbury, NJ  -- October 7, 2014 – Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors.
July 16, 2014
Strides Arcolab makes strategic investment in Oncobiologics
July 16, 2014:  Cranbury, NJ  Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc, a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.
June 26, 2014
Liomont and Oncobiologics partner to launch Biosimilars in Mexico
Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market.  The scope of the agreement includes exclusive
June 12, 2014
Oncobiologics launches Phase I Clinical Trial for ONS-3010 Biosimilar version of Humira®
Cranbury, NJ – June 12, 2014 — Oncobiologics, Inc. announced today that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira®. After reviewing Oncobiologics’ Clinical Trial
June 2, 2014
Ipca and Oncobiologics Create Strategic Biosimilars Partnership
Mumbai, India and New Jersey, USA – June 2, 2014 — Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products.  Under the
May 23, 2014
Oncobiologics CEO named finalist in EY Entrepreneur Of The Year 2014 New Jersey program
Oncobiologics Founder and CEO Pankaj Mohan, Ph.D. was named a finalist in the EY Entrepreneur Of The Year 2014 for New Jersey program. This award recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment
Displaying 41 - 48 of 48